Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01953926 · ClinicalTrials.gov registry record · Phase 2
Basket Study of Neratinib in Participants With Solid Tumors Harboring Somatic HER2 or EGFR Exon 18 Mutations
A Phase 2 study, sponsored by Puma Biotechnology.
- Terminated
- Registry status
- Phase 2
- Development phase
- 582
- Enrollment target
NCT01953926 is a Phase 2 study that was terminated before completion, run by Puma Biotechnology. The registered enrollment target is 582 participants.
The verdict
NCT01953926, a Phase 2 study, was terminated before completion, sponsored by Puma Biotechnology.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 582 participants
- Enrollment target
Study Summary
This is an open-label, multicenter, multinational, Phase 2 basket study exploring the efficacy and safety of neratinib as monotherapy or in combination with other therapies in participants with HER (EGFR, HER2) mutation-positive solid tumors.
Interventions
- DRUG Trastuzumab
- DRUG Neratinib
- DRUG Paclitaxel
- DRUG Fulvestrant
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 582 participants |
| Start Date | 2013-09-30 |
| Est. Completion | 2023-01-02 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01953926
The ClinicalTrials.gov registry entry for NCT01953926 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 582 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Puma Biotechnology, which has 28 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Trastuzumab is the first listed.
NCT01953926 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01953926 about?
NCT01953926 is a clinical study titled "Basket Study of Neratinib in Participants With Solid Tumors Harboring Somatic HER2 or EGFR Exon 18 Mutations". This is an open-label, multicenter, multinational, Phase 2 basket study exploring the efficacy and safety of neratinib as monotherapy or in combination with other therapies in participants with HER (EGFR, HER2) mutation-positive solid tumors.
What is the current status of trial NCT01953926?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 582 participants. The study started on 2013-09-30. Estimated completion is 2023-01-02.
What interventions are being tested in trial NCT01953926?
The interventions under investigation include: Trastuzumab (DRUG), Neratinib (DRUG), Paclitaxel (DRUG), Fulvestrant (DRUG).
Who is sponsoring clinical trial NCT01953926?
This trial is sponsored by Puma Biotechnology, which has 28 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.